diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5405diaendo-5405Research ArticleСтатьиArticlesЗарегистрированы новые препараты для лечения сахарного диабета - Галвус и Галвус МетGalvus and Galvus Met, new registered medicinal agents for the treatment of diabetes mellitusСахарный диабетредакция журналаDiabetes MellitusEditorial teamdia@endojournals.ru200915062009122№2 (2009)8485Copyright © Сахарный диабет р., 20092009Сахарный диабет р.Diabetes Mellitus E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5405сахарный диабетновые препаратыГалвусГалвус Метdiabetes mellitusnew drugsGalvusGalvus MetReferencesLangley AK., Suffoletta TJ et al. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007; 27:1163-80.Langley AK., Suffoletta TJ et al. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy 2007; 27:1163-80.Fonseca V, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007; 50: 1148-1155.Fonseca V, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007; 50: 1148-1155.A. J. Garber, R.-P. Camisasca et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM). Diabetes Obes Metab 10: 1047-1056.A. J. Garber, R.-P. Camisasca et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM). Diabetes Obes Metab 10: 1047-1056.Schweizer A, Couturier A., Foley JE et al. Comparison between vildagliptin and metformin to sustain reduction in HbA1c over 1 year in drug-naive patients with Type 2 Diabetes. Diabet Med. 2007; 24: 955-961.Schweizer A, Couturier A., Foley JE et al. Comparison between vildagliptin and metformin to sustain reduction in HbA1c over 1 year in drug-naive patients with Type 2 Diabetes. Diabet Med. 2007; 24: 955-961.Rosenstock J, Baron MA., Dejager S et al. Comparison of vildagliptin and rosiglitazone Monotherapy in patients with Type 2 Diabetes: a 24-week, double-blinde, randomized trial. Diabetes Care 2007, 30: 217-23.Rosenstock J, Baron MA., Dejager S et al. Comparison of vildagliptin and rosiglitazone Monotherapy in patients with Type 2 Diabetes: a 24-week, double-blinde, randomized trial. Diabetes Care 2007, 30: 217-23.Bosi E, Camisasca RP et al.. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007; 30: 890-895 .Bosi E, Camisasca RP et al.. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007; 30: 890-895 .R. Marfella, M. Barbieri et al. Effects of vildagliptin twice daily versus sitagliptin once daily on 24-hour acute glucose fluctuations. Journal Diabetes and its Complications, 2009, in press.R. Marfella, M. Barbieri et al. Effects of vildagliptin twice daily versus sitagliptin once daily on 24-hour acute glucose fluctuations. Journal Diabetes and its Complications, 2009, in press.
The authors declare that there are no conflicts of interest present.